BioCentury | Sep 1, 2020
Product Development

Aug. 31 Quick Takes: Mylan, Biocon launch cheaper insulin in U.S.; plus: AZ, bluebird, Lipocine, Amgen, AbbVie-Morphic, Polyphor-Fosun and Milestone

...$148 million in sales milestones, plus low double-digit to mid-teen royalties. Milestone reopening Phase III of etripamil...
...in late 2021 or early 2022 from its Phase III RAPID (formerly NODE-301B) study of etripamil...
BioCentury | Mar 24, 2020
Product Development

Milestone says trial design trips up etripamil in tachycardia Phase III

...design and that the data support efficacy. Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is continuing to evaluate etripamil...
...minutes, 95% CI: 31,101; p=0.12). In a statement, Milestone President and CEO Joseph Oliveto said etripamil...
...evaluating etripamil for PVST as well as results from NODE-301 with regulators. Sandi Wong, Assistant Editor etripamil (MSP-2017) Milestone...
BioCentury | May 9, 2019
Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

...million. The price valued Milestone at $354.7 million. Its lead program, calcium channel-blocking nasal spray etripamil...
BioCentury | Oct 26, 2018
Financial News

Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

...self-administered acute paroxysmal supraventricular tachycardia (PSVT) treatment, etripamil. Milestone began a Phase III study of etripamil...
...the at home setting." The new funds will also support select commercial prelaunch activities for etripamil...
...and Fonds de solidarité FTQ. Next year Milestone plans to start proof-of-concept clinical studies of etripamil...
BioCentury | Oct 25, 2018
Financial News

Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

...self-administered acute paroxysmal supraventricular tachycardia (PSVT) treatment, etripamil. Milestone began a Phase III study of etripamil...
...the at home setting." The new funds will also support select commercial prelaunch activities for etripamil...
...potential to fill unmet medical needs beyond what we can achieve with etripamil." Elizabeth S. Eaton etripamil (MSP-2017) Milestone...
BioCentury | Aug 4, 2017
Finance

Milestone's options

...Milestone Pharmaceuticals Inc. turned positive Phase II data for etripamil into an upsized $55 million series...
...President and CEO Joe Oliveto said Milestone had planned to raise $45 million to bring etripamil...
...PSVT) by mid-2019. The trial is slated to begin late this year or early next. Etripamil...
BioCentury | Aug 4, 2017
Clinical News

Milestone's etripamil meets in Phase II for PSVT

...paroxysmal supraventricular tachycardia (PSVT) showing that 70, 105 and 140 mg doses of intranasal etripamil (MSP-2017...
...to receive placebo or 35, 70, 105 or 140 mg etripamil. The lowest dose of etripamil...
...all 4 etripamil arms, median time to PSVT conversion ranged from 1.82 to 3.03 minutes. Etripamil...
BioCentury | Aug 4, 2017
Financial News

Milestone closes first tranche of $55M series C

...and GO Capital. The company expects a final close this year. Milestone's lead candidate, etripamil (MSP-2017...
...trial of etripamil to treat paroxysmal supraventricular tachycardia (PSVT). Milestone Pharmaceuticals Inc. , Montreal, Quebec Kevin Lehnbeuter etripamil MSP-2017 Milestone...
BioCentury | Aug 1, 2017
Financial News

Milestone raises $55M in series C

...GO Capital. Milestone will use the funds to advance the company's lead candidate, etripamil ( MSP-2017...
...intranasally administered calcium channel blocker. Novo's Nilesh Kumar and Forbion's Marco Boorsma joined Milestone's board. Virginia Li etripamil MSP-2017 Milestone...
BioCentury | Nov 4, 2013
Clinical News

MSP-2017: Phase I started

...intranasal formulations of MSP-2017 in healthy adult volunteers. Milestone Pharmaceuticals Inc. , Montreal, Quebec Product: MSP-2017...
Items per page:
1 - 10 of 12